ClinicalTrials.gg
CompletedNCT02133807LaRCAUpdated May 12, 2014

Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis

A Phase 3 interventional study of Specific Lp(a) apheresis in Atherosclerosis, Coronary Disease and Carotid Artery Diseases, sponsored by Russian Cardiology Research and Production Center. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-05-12.

Sponsored by Russian Cardiology Research and Production Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Atherosclerosis with a site in Russian Federation — 5 open to participants now, 5 under way, none of them phase 3. Atherosclerosis · Russian Federation.

Enrollment
26th of 27
32 · median 200
Started
2009
with 2 others
Phase 3
8 of 35
none open now
Registered
15th of 35
by date
Lead sponsor
3 of 35
Russian Cardiology Research and Production Center

Among the 35 studies in Atherosclerosis with a site in Russian Federation, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 8 in phase 3, and was the 15th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 35 studies in Atherosclerosis with a site in Russian Federation are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Atherosclerosis with a site in Russian Federation, or all of them as a file.
02

Study summary

To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a) levels.

Read the detailed description

Following the hypothesis that if Lp(a) excess has a pathogenic role in atherogenesis, then specific elimination of circulating Lp(a) should affect plaque growth and stability, we evaluated the efficacy of Lp(a) apheresis on changes in coronary plaque volume and composition and carotid intima-media thickness in patients with CHD on the background of optimal medical treatment.

03

Conditions studied

  • Atherosclerosis
  • Coronary Disease
  • Carotid Artery Diseases

Keywords

  • Lipoprotein(a);
  • Lp(a) immunoadsorption;
  • Apheresis;
  • Coronary atherosclerosis;
  • Carotid Atherosclerosis;
  • Intima-media thickness;
  • Regression;
  • Quantitative Coronary Angiography;
  • Intravascular Ultrasound;
  • Virtual Histology;
  • Plaque;
  • Atorvastatin;
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable coronary heart disease (CHD) requiring a clinically indicated coronary angiography.
  • Lp(a) ≥50 mg/dL
  • LDL-C \<2.6 mmol/L (100 mg/dL)
  • Signed written form to participate in the study

Exclusion criteria

Exclusion Criteria:

  • history of acute coronary syndrome or surgical intervention within prior 3 months to inclusion
  • chronic infectious and inflammatory diseases
  • familial hypercholesterolemia
  • TG ≥4.5 mmol/L (400 mg/dL)
  • Active liver disease ( or AST >3 (ULN), or total >1.5 ULN);
  • CK ≥3 ULN;
  • Thyroid dysfunction;
  • Renal dysfunction ( (Cockcroft-Gault Equation) ≤30 ml/min);
  • Uncontrolled diabetes ( ≥7.0%);
  • Coagulopathies;
  • Lipid-lowering drugs, except statins for the last month
  • Known statin or immunoadsorption intolerance
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Specific Lp(a) apheresis & Atorvastatin

    Specific Lp(a) apheresis was performed with "Lp(a) Lipopak" immunosorbent columns ("POCARD" Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD.

    Procedure: Specific Lp(a) apheresis

  • No intervention
    Atorvastatin

    Standard medical therapy in accordance with the recommendations for secondary prevention of CHD

Interventions

  • ProcedureSpecific Lp(a) apheresis

    Specific Lp(a) apheresis procedures were carried out weekly with "Lp(a) Lipopak" columns (POCARD Ltd., Moscow, Russia) according to the standard protocol

    Also known as: "Lp(a) Lipopak" immunoadsorption columns

06

What researchers measure

Primary outcomes

  1. Change in Percent Diameter Stenosis

    The absolute change from baseline to 18 months in mean percent diameter stenosis, determined by quantitative coronary angiography (QCA) as the narrowest lesion in each segment and calculated as: ((reference diameter-minimal lumen diameter (MLD))/reference diameter)x100.

    Time frame: From Baseline to End of Study (Week 72)

Secondary outcomes

  1. Change in mean carotid intima-media thickness (IMT)

    Change from baseline in mean carotid IMT, as measured by duplex ultrasonography of common carotid arteries after 9 and 18 months.

    Time frame: From Baseline to Week 36 (9 months) and to Week 72 (18 months)

  2. Numbers of Coronary segments Showing Regression

    Clinically relevant regression or progression was defined as a change from baseline to follow up of ≥10% for percent diameter stenosis

    Time frame: From baseline to End of study (Week 72)

  3. Number of Carotid Segments showing Regression

    Carotid IMT progression criterion for the 18 months of treatment was considered as growth rate of 0.02 mm (0.015 mm/yr). No changes or reduction in carotid IMT ≥ 0,02 mm served as criterion of stabilization and regression of carotid atherosclerosis, respectively.

    Time frame: From Baseline to End of study (Week 72)

  4. Change in total atheroma volume (TAV) from baseline to 18 months post-therapy

    TAV at baseline - TAV at Week 72 assessed by intravascular ultrasound (IVUS) imaging of a targeted coronary artery

    Time frame: From Baseline to Week 72

  5. Change in absolute volumes of plaque components

    Mean change in absolute volumes of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy

    Time frame: From Baseline to Week 72

  6. Change in relative amount of plaque components

    Mean change in relative amounts of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy

    Time frame: From baseline to Week 72

  7. Numbers of Coronary Plaques Showing Regression

    Regression was defined as decrease in TAV for all anatomically comparable cross sectional areas of targeted coronary artery from baseline of ≥ 0,1 mm cubed

    Time frame: From baseline to End of study (Week 72)

  8. Acute change in Lp(a) level

    Difference in Lp(a) concentration before and after specific Lp(a) apheresis procedure calculated as the mean of all measurements

    Time frame: Once a week over 72 week period of active treatment

  9. Change in quality of life (QOL)

    To evaluate the impact of the specific Lp(a) removal therapy on the quality of life using Seattle Angina Questionnaire (SAQ) and Exercise stress test as compared with standard guideline-driven medical therapy of CHD patients

    Time frame: from baseline to week 72

Other outcomes

  1. Total Cholesterol (TC) Serum Level

    Mean changes in TC level over the 18-month study period

    Time frame: From Baseline to Week 4, 36, 72

  2. Lipoprotein(a) (Lp(a)) serum levels

    Mean changes in Lp(a) level over the 18-month study period

    Time frame: From Baseline to Week 4, 36, 72

  3. Low-density lipoprotein cholesterol (LDL-C) serum Level

    Mean changes in LDL-C level over the 18-month study period

    Time frame: From Baseline to Week 4, 36, 72

  4. Change in corrected LDL-C (LDL-C corr) Serum level

    Since all included patients had high Lp(a) levels, to avoid overestimation of LDL-C fraction estimated LDL-C levels were corrected for cholesterol derived from Lp(a). Corrected LDL-C (LDL-C corr) was calculated using Dahlen's modification of the Friedewald formula: LDL-C corr = TC - (HDL-C) - (TG / 2.2) - (0.3 x Lp(a) / 38.7). For values in mmol/L, Lp(a) in mg/dL

    Time frame: From Baseline to Week 4, 36, 72

  5. Change in triglycerides (TG) serum Level

    Mean changes in TG level over the 18-month study period

    Time frame: From Baseline to Week 4, 36, 72

  6. Change in high-density lipoprotein cholesterol (HDL-C) serum level

    Mean changes in HDL-C level over the 18-month study period

    Time frame: From Baseline to Week 4, 36, 72

  7. Change in hemoglobin level

    Time frame: From Baseline to Week 4, 36, 72

  8. Change in creatinine level

    Time frame: From Baseline to Week 4, 36, 72

  9. Change in creatine kinase (CK) level

    Time frame: From Baseline to Week 4, 36, 72

  10. Change in alanine transaminase (ALT) level

    Time frame: From Baseline to Week 4, 36, 72

  11. Change in aspartate transaminase (AST) level

    Time frame: From Baseline to Week 4, 36, 72

07

Study locations

1 site
  • Russian Cardiology Research and Production Center
    Moscow, 121552, Russian Federation
08

References and documents

Publications

  • Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, Utkina EA, Konovalov GA, Pokrovsky SN. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013 Jan;14(1):93-9. doi: 10.1016/j.atherosclerosissup.2012.10.015. PubMed 23357149 ↗
  • Pokrovsky SN, Afanasieva OI, Safarova MS, Balakhonova TV, Matchin YG, Adamova IYU, Konovalov GA, Ezhov MV. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity. Atheroscler Suppl. 2017 Nov;30:166-173. doi: 10.1016/j.atherosclerosissup.2017.05.004. Epub 2017 May 31. PubMed 29096833 ↗
  • Pokrovsky SN, Afanasieva OI, Ezhov MV. Lipoprotein(a) apheresis. Curr Opin Lipidol. 2016 Aug;27(4):351-8. doi: 10.1097/MOL.0000000000000319. PubMed 27213629 ↗
  • Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. Atheroscler Suppl. 2015 May;18:163-9. doi: 10.1016/j.atherosclerosissup.2015.02.025. PubMed 25936321 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2014
First posted
May 8, 2014
Start
Sep 2009
Primary completionActual
Mar 2012
CompletionActual
Jun 2012
Last update
May 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02133807
Lead sponsor
Russian Cardiology Research and Production Center
Collaborators
Clinical Diagnostic Center MEDSI, Moscow State Government
Responsible party
Professor Sergei Pokrovsky, PhD, DSc (Chair of the Laboratory of Atherosclerosis, Russian Cardiology Research and Production Center) — Principal investigator
First posted
May 8, 2014
Start date
Sep 2009
Primary completion
Mar 2012
Completion
Jun 2012
Last update
May 12, 2014

Study contacts

Sergei Pokrovsky, PhD, DSc
principal investigator · Russian Cardiology Research and Production Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion